Cancers 2022 November 30 [Link] Rita Terenziani, Maricla Galetti, Silvia La Monica, Claudia Fumarola, Silvia Zoppi, Roberta Alfieri, Graziana Digiacomo, Andrea Cavazzoni, Delia Cavallo, Massimo Corradi, Marcello Tiseo, Pier Giorgio Petronini, Mara Bonelli Abstract Background: The loss of the CDKN2A/ARF (cyclin-dependent kinase inhibitor 2A/alternative reading frame) gene is the most common alteration in malignant pleural…

Read More

Frontiers in Pharmacology 2022 October 11 [Link] Sze-Kwan Lam, Sheng Yan, Joyce Sze-Man Lam, Yuqian Feng, Mahjabin Khan, Caoyang Chen, Frankie Chi-Fat Ko, James Chung-Man Ho Abstract Background: Inhalation of asbestos fibers is the most common cause of malignant pleural mesothelioma (MPM). In 2004, the United States Food and Drug Administration approved a combination of…

Read More

Experimental Oncology 2022 August [Link] D Endoh, K Ishii, K Kohno, N Virgona, Y Miyakoshi, T Yano, T Ishida Abstract Background: Hypoxia has been noted as a key factor for induction and maintenance of cancer stemness thereby leading to therapy resistance. Three-dimensional (3D) spheroid models demonstrate a heterogeneity of hypoxic regions replicating the in vivo…

Read More

Targeted Oncology 2022 July [Link] Fatéméh Dubois, Céline Bazille, Jérôme Levallet, Elodie Maille, Solenn Brosseau, Jeannick Madelaine, Emmanuel Bergot, Gérard Zalcman, Guénaëlle Levallet Abstract Malignant pleural mesothelioma is a rare and aggressive neoplasm, which has primarily been attributed to the exposure to asbestos fibers (83% of cases); yet, despite a ban of using asbestos in…

Read More

Targeted Oncology 2022 July 30 [Link] Fatéméh Dubois, Céline Bazille, Jérôme Levallet, Elodie Maille, Solenn Brosseau, Jeannick Madelaine, Emmanuel Bergot, Gérard Zalcman, Guénaëlle Levallet Abstract Malignant pleural mesothelioma is a rare and aggressive neoplasm, which has primarily been attributed to the exposure to asbestos fibers (83% of cases); yet, despite a ban of using asbestos…

Read More

World Journal of Surgical Oncology 2022 June 29 [Link]Jianting Ma, Shengzhi Zhang Abstract Background: Prognosis in malignant peritoneal mesothelioma (MPM) remains poor, and the associated factors are unclear. Therefore, this study aimed to investigate the prognostic factors of MPM. Methods: A total of 52 female MPM patients treated in 2012-2017 were retrospectively analyzed. Kaplan-Meier survival…

Read More

The Lancet Oncology 2022 May 16 [Link] Marjorie G Zauderer, Peter W Szlosarek, Sylvestre Le Moulec, Sanjay Popat, Paul Taylor, David Planchard, Arnaud Scherpereel, Marianna Koczywas, Martin Forster, Robert B Cameron, Tobias Peikert, Evren Kocabaş Argon, Neil R Michaud, Attila Szanto, Jay Yang, Yingxue Chen, Vikram Kansra, Shefali Agarwal, Dean A Fennell Abstract Background: Treatment…

Read More

Translational Lung Cancer Research 2022 April [Link] Rong Sun, Ryosuke Tanino, Xuexia Tong, Eshat Fahmida Haque, Yoshihiro Amano, Takeshi Isobe, Yukari Tsubata Abstract Background: Acquired pemetrexed resistance leads to treatment interruption in patients with malignant pleural mesothelioma (MPM). Insulin-like growth factor-I receptor (IGF-1R) inhibitor is a candidate for treating pemetrexed-naïve MPM. However, the efficacy of…

Read More